

Regional bulletin for the availability of antimalarial medicines: Second Quarter 2014

Volume 2 Number 1
2014



Plataforma Regional sobre
Acceso e Innovación para
Tecnologías Sanitarias
PRAIS

www.paho.org/prais

This bulletin is developed through a collaborative effort between the National Malaria Control Programs of the Region of the Americas, PAHO/WHO and SIAPS/USAID to facilitate sharing of information between countries in the Americas. The objectives of the bulletin are to increase awareness of stocks of antimalarial medicine, generate stock out alerts and promote exchanges and donations of antimalarial medicines between countries.

This bulletin is based on information provided by countries in South and Central America who participate in the Amazon Malaria Initiative (AMI) and are members of the Amazon Network for the Surveillance of Antimalarial Drug Resistance (RAVREDA). The bulletin offers information on the availability of medicines in central and regional medical stores that allow countries' decision makers to assure uninterrupted supply.

The following tables detail the availability of antimalarial medicines for each country. Stock out is considered zero availability in the storerooms.

The indicator of months of availability is calculated by each country by dividing the availability of medicines by the average monthly consumption or distribution. The average consumption is found by dividing the distribution or consumption over the previous year by 12.

This second bulletin includes information from nine countries, five from South America and four from Central America. Seven countries sent central and regional level data.



Availability of medicines for the second quarter, 2014

Medications		BELIZE					BRASIL					COLOMBIA					
		Central			Department		Central			Department		Central			Department		
		Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet					1	750	0.48			1	564	1.04	3,018	5.92	
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet					1	2,220	1.08			1	2,160	0.82	12,012	3.38	
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet					1	1,320	0.60			1	21,780	3.00	55,332	7.53	
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	5.00	0.00	0.00	0.00	1	27,870	6.55			1	123,816	2.53	205,200	4.44
	005	Artesunate 50 mg tablet															
	006	Artesunate 100 mg tablet															
	007	Artesunate 250 mg tablet															
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.						1	1,630	36.22							
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.						1	2,310	48.13							
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.						1	2,480	29.52							
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.						1	14,550	184.18							
	015	Mefloquine 250 mg tablet	0	700	14.00	100	10.00										
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet															
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	98,290	9.83	17,200	3.74	1	1,789,000	6.49			1	967,430	14.52	523,391	8.82
	018	Chloroquine phosphate 100 mg tablet															
	019	Primaquine phosphate 5 mg tablet	1	0	0.00	0	0.00	1	979,500	7.61			1	227,885	12.3	286,799	18.39
	020	Primaquine phosphate 7.5 mg tablet															
	021	Primaquine phosphate 15 mg tablet	1	2,000	28.57	5,396	77.09	1	4,090,000	12.42			1	75,560	0.88	187,103	2.43
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	22,404	25.20							
	023	Artesunate rectal 50 mg										1	4,728	14.78	2,770	5.33	
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule						1	90,500	47.48			1	1,052	5.51	1,303	2.78
	026	Clindamycin Hydrochloride 300 mg Capsule						1	0	0.00							
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						1	0	0.00							
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule						1	13,155	0.97							
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	0.00	0.00	0.00			1	0	0.00			1	1,964	6.55	1,818	1.92
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable															
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable															
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable															
036	Quinine Sulfate 300mg tablet	0	200									1	167,386	65.18	27,842	16.57	
037	Quinine Sulfate 500 mg tablet						1	91,500	11.97								

Source: Consolidated National Report from Countries

Availability of medicines for the second quarter, 2014

Medications			ECUADOR					GUYANA					HONDURAS					
			Central			Department		Central			Department		Central			Department		
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	148	110.31	71	52.92	1	0	0.00								
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	261	194.53	588	438.26	1	469,800	5,222.00								
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	65	48.45	1,325	987.58	1	72,900	540.00								
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	5	0.37	3,022	225.24	1	2,701,440	108.42								
	005	Artesunate 50 mg tablet																
	006	Artesunate 100 mg tablet																
	007	Artesunate 250 mg tablet																
	008	Artesunate+ SP (Children)																
	009	Artesunate+ SP (Adolescent)																
	010	Artesunate+ SP (Adults)																
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.																
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.																
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.																
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.																
	015	Mefloquine 250 mg tablet							1	0	0.00							
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet										1	0	0.00	0	0.00		
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	34,945	193.24	11,698	64.69	1	59,700	2.21				1	910,370	13.30	305,901	7.24
	018	Chloroquine phosphate 100 mg tablet																
	019	Primaquine phosphate 5 mg tablet												1	0	0.0	0	0.00
	020	Primaquine phosphate 7.5 mg tablet	1	0	0.00	3,394	134.06	1	18,000	1.93								
	021	Primaquine phosphate 15 mg tablet	1	1,955	7.72	22,740	89.82	1	88,300	2.36				1	699,970	13.52	59,379	2.35
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	1,897	210.78								
	023	Artesunate rectal 50 mg																
	024	Artesunate rectal 100 mg																
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule	1	18	1.34	148	11.03											
	026	Clindamycin Hydrochloride 300 mg Capsule	1	1,320	98.39	275	20.50											
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable																
	028	Clindamycin Hydrochloride 150 mg Capsule																
	029	Clindamycin 75mg/5mL suspension																
	030	Doxycycline 100 mg Capsule																
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable																
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable																
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable																
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable										1	0	0.00	0	0.00		
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable							1	6,304	114.62							
	036	Quinine Sulfate 300mg tablet	1	269	4.77	1,143	20.28					1	0	0.00	0	0.00		
	037	Quinine Sulfate 500 mg tablet																

Availability of medicines for the second quarter, 2014

Medications			NICARAGUA				PANAMA				PERU						
			Central			Department		Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet					1	180	7.50	0	0.00						
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet					1	360	15.00	0	0.00						
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet					1	540	22.50	0	0.00						
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet					1	720	30.00	710	29.58						
	005	Artesunate 50 mg tablet										1	151,328	230.68	59,592	90.84	
	006	Artesunate 100 mg tablet															
	007	Artesunate 250 mg tablet										1	17,058	8.69	32,889	16.76	
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.															
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.															
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.															
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.															
	015	Mefloquine 250 mg tablet										1	5,014	1.28	7,621	1.94	
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet					0	9,000									
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	352,470	3.42	897,475	4.03	1	142,000	2.45	34,810	14.18	1	204,490	6.04	500,249	14.78
	018	Chloroquine phosphate 100 mg tablet															
	019	Primaquine phosphate 5 mg tablet	1	592,622	8.89	453,691	3.77	1	15,000	3.00	0	0.00	1	0	0.00	0	0.00
	020	Primaquine phosphate 7.5 mg tablet											1	0	0.00	0	0.00
	021	Primaquine phosphate 15 mg tablet	1	121,672	1.83	501,607	3.67	1	370,000	12.33	52,920	15.12	1	400,590	8.46	369,336	7.80
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules															
	023	Artesunate rectal 50 mg															
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule										0	23		112		
	026	Clindamycin Hydrochloride 300 mg Capsule	1	1,394,560	16.40	209,468	1.75										
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable															
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule															
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	1	1,231	13.83	269	2.99										
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable																
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable										1	11,116	102.93	426	3.94		
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable																
036	Quinine Sulfate 300mg tablet										1	1,000	2.70	4,091	11.03		
037	Quinine Sulfate 500 mg tablet																

Source: Consolidated National Report from Countries

Indicators reported for the second quarter, 2014

INDICATORS	Belize		Brasil		Colombia		Ecuador		Guyana		Honduras		Nicaragua		Panama		Peru	
	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart
No. of department warehouses that report medication availability data.		7				36		9				20		18		14		33
% of regional stores that report stockout in one or more antimalarials required by the Standard Treatment Guidelines (STG).		100%				47%		64%				100%		6%		7%		7%
Number of medicines required in the Standard Treatment Guidelines (STG)	4	4	18		11	11	10	10	10		6	6	5	5	7	7	7	7
Number of STG medicines that are available.	2	2	15		11	11	9	10	8		2	2	5	5	7	3	7	3
% of STG medications available	50%	50%	83%		100%	100%	90%	100%	80%		33%	33%	100%	100%	100%	43%	100%	43%
% of STG medications not available	50%	50%	17%		0%	0%	10%	0%	20%		67%	67%	0%	0%	0%	57%	0%	57%
% of STG medications with availability less than the minimum security stock (3 months)	50%	50%	39%		45%	27%	30%	0%	50%		67%	83%	20%	40%	29%	57%	29%	57%
% of STG medications which are overstocked (more than 24 months of availability)	25%	25%	33%		9%	0%	50%	70%	50%		0%	0%	0%	0%	14%	14%	14%	14%

This bulletin was elaborated within the framework of AMI/RAVREDA with assistance from PAHO/WHO, specifically the Medicines and Health Technologies (HSS/MT) unit and the Regional Malaria Program (CHA/VT) and the USAID funded program Systems for Improved Access to Pharmaceuticals and Services (SIAPS). Data for the report was sent by the National Malaria Control Programs of the participating countries. The consolidation and editing of the bulletin was completed by the regional team of the PAHO/WHO Strategic Fund, which utilized the previous format developed by DIGEMID and SIAPS/USAID as a reference

